Welcome to our dedicated page for Pasithea Therapeutics Warrants news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics Warrants stock.
Pasithea Therapeutics Corp is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. Leveraging expertise in neuroscience, translational medicine, and drug development, the company's pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has appointed Alfred J. Novak to its Board of Directors, replacing Dr. Yassine Bendiabdallah, who stepped down on September 14, 2022. Mr. Novak brings over 30 years of experience in life sciences, with a history of significant financial transactions and successful exits, including Dova Pharmaceuticals and Biosense. Chairman Lawrence Steinman expressed enthusiasm for Mr. Novak's contributions toward advancing Pasithea's drug candidates. The company specializes in developing treatments for CNS disorders and providing ketamine infusion services.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has appointed Dr. Merit Cudkowicz to its Scientific Advisory Board, bringing extensive expertise in ALS and neurological diseases. Dr. Cudkowicz, Chief of Neurology at Massachusetts General Hospital, has significantly advanced ALS research and clinical trials. Her collaboration is expected to enhance Pasithea's development of its monoclonal antibody targeting alpha-5/beta-1 integrin, which shows promising preclinical efficacy. Dr. Cudkowicz’s insights are poised to drive innovation in treatment approaches for ALS.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced that CEO Dr. Tiago Reis Marques will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation is scheduled for September 12, 2022, at 7:00 AM ET. Attendees can request virtual one-on-one meetings through H.C. Wainwright. A pre-recorded presentation will also be available on the Company’s website. Pasithea focuses on researching treatments for psychiatric and neurological disorders, including IV ketamine infusions for patients in clinical and home settings.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) will present preclinical results of its DNA vaccine, PAS002, targeting multiple sclerosis at the conference 'From Laboratory to Clinic: Medicine after COVID' on August 30, 2022, at Trinity College, Oxford University. The conference, established in 1984, unites researchers to share advancements in immunology and molecular medicine. CEO Dr. Tiago Reis Marques expressed optimism about the findings contributing to new treatments for neurological disorders. The keynote will be delivered by Professor Lawrence Steinman, along with other leading experts in the field.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced positive results from a preclinical study of its tolerizing vaccine, PAS002, targeting multiple sclerosis (MS). The study involved a mouse model of relapsing-remitting experimental autoimmune encephalomyelitis, demonstrating significant efficacy in reducing disease severity and relapse rates (p<0.001). Key findings include delays in paralysis onset and a 50% prevention rate of disease. PAS002 leverages the GlialCAM protein, which also relates to monkeypox virus, potentially expanding its therapeutic applications. The company has filed a provisional patent and aims for rapid development.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has filed a consent revocation statement in response to a solicitation by the Camac Group to call a Special Meeting of Stockholders. The Board unanimously recommends that stockholders reject this effort, viewing it as a self-serving attempt that could undermine the Company's progress and potential value. Pasithea, focused on groundbreaking therapies for psychiatric and neurological disorders, aims to protect stockholder interests and has raised over $55 million since its IPO in September 2021. The company warns that a successful takeover could lead to cash depletion and hinder its development efforts.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced a AUD $1 million (U.S. $694,000) grant from FightMND for drug development related to ALS treatments. This funding, part of Pasithea's acquisition of Alpha-5 Integrin, LLC, will support research into monoclonal antibodies targeting the alpha-5/beta-1 integrin. These candidates are aimed at improving outcomes for ALS patients, a disease without a known cure. The grant provides non-dilutive funding that will expedite preclinical testing in mouse models.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has announced its acquisition of Alpha-5 integrin, LLC, for an enterprise value of $3.75 million, consisting of 3.26 million shares of Pasithea common stock and 1 million warrants. Alpha-5 is developing a novel monoclonal antibody for treating amyotrophic lateral sclerosis (ALS) and other neuroinflammatory disorders. The acquisition enhances Pasithea's pipeline and includes proprietary technology and a skilled scientific team. A webcast will be held on June 22, 2022, to discuss further details.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced that CEO Tiago Reis Marques will present at NobleCon18 on April 21, 2022, at 12:30 p.m. ET in Hollywood, FL. The company focuses on developing new treatments for psychiatric and neurological disorders and offers access to IV ketamine infusions for patients with mental illness. This presentation will highlight Pasithea's innovative approaches and commitment to addressing mental health needs.
Pasithea Therapeutics (Nasdaq: KTTA) reports a strong cash balance of $52.9 million, supporting operations into 2024. The company has initiated drug development programs in schizophrenia and multiple sclerosis, partnering with Evotec for new chemical entities and conducting preclinical work at Hooke Labs. Additionally, Pasithea has launched ketamine clinics in the U.K. and U.S., generating revenue. They plan to open new clinics and expand services throughout 2022.
FAQ
What is the current stock price of Pasithea Therapeutics Warrants (KTTAW)?
What is Pasithea Therapeutics Corp focused on?
What is included in Pasithea Therapeutics Corp's pipeline?
What areas of expertise does Pasithea Therapeutics Corp leverage?
Who can be contacted for corporate communications at Pasithea Therapeutics Corp?
When is the initial safety, tolerability, and biomarker data expected to be reported?
When is the initial interim safety and PK data release on track for?
What diseases does Pasithea Therapeutics Corp focus on?
What is Pasithea Therapeutics Corp's primary area of research?
What is the core mission of Pasithea Therapeutics Corp?
How does Pasithea Therapeutics Corp contribute to the field of medicine?
